Treatment of Obesity with Thyroid hormones in Europe. Data from the THESIS* Collaboration.
Juan Carlos GalofréJuan José DíezRoberto AttanasioEndre Vezekenyi NagyRoberto NegroEnrico PapiniPetros PerrosMilosˇ ZˇarkovićErsin AkarsuMaria AlevizakiGöksun AyvazTomasz BednarczukBiljana Nedeljković BeleslinEszter BertaMiklos BodorAnna Maria BorissovaMihail A BoyanovCamille BuffetMaria-Cristina BurlacuHarald DobnigValentin V FadeevBenjamin C T FieldEric FliersDagmar FuhrerTommi T HakalaJiskra JanPeter Andreas KoppMichael R KrebsM KršekMartin KužmaMikael LantzIvica LazúrováLaurence LeenhardtVitaliy LuchytskiyFrancisca Marques PugaAnne McGowanSaara MetsoCarla MoranTatyana MorgunovaDan Alexandru NiculescuBožidar PerićTereza PlanckCătălina PoianăEyal RobenshtokPatrick Olivier RosseletMarek RuchalaKamilla Ryom RiisAlla ShepelkevichMykola D TronkoDavid UnuaneIrfan VardarliW. Edward VisserAndromachi VryonidouYounes Ramazan YounesLaszlo HegedüsPublished in: Journal of endocrinological investigation (2024)
Despite the lack of evidence, and contrary to guidelines' recommendations, about 5% of respondents stated that TH may be indicated as a treatment for obesity in euthyroid patients resistant to life-style interventions. This opinion was associated with (i) respondent characteristics: being non-endocrinologist, working in private practice, treating a small number of hypothyroid patients annually and (ii) national characteristics: prevalence of obesity, Eastern Europe, low GNI and lack of national hypothyroidism guidelines.
Keyphrases
- end stage renal disease
- metabolic syndrome
- insulin resistance
- type diabetes
- ejection fraction
- weight loss
- chronic kidney disease
- newly diagnosed
- healthcare
- peritoneal dialysis
- clinical practice
- weight gain
- quality improvement
- primary care
- high fat diet induced
- physical activity
- risk factors
- health insurance
- replacement therapy
- electronic health record
- skeletal muscle
- big data
- patient reported
- data analysis